Company (Symbol)

Date Filed

Date Comm.

Shares/Units

Price

Shares Out (M)

Lead, Other Underwriters

Gross ($M)

Net ($M)

I. COMMENCED TRADING IN APRIL

INITIAL OFFERINGS

Actelion AG (Swtizerland; SWX New Exchange: ATLN)1

3/2

4/6

9S

CHF260 $155.21

4.6

Credit Suisse First Boston

CHF234 US$139.7

N/A

Exelixis Pharmaceuticals Inc. (EXEL)2

2/7

4/10

10.465S

$13

44.1

Goldman, Sachs & Co. Credit Suisse First Boston SG Cowen Securities

$136.0

$125.1

Ixion Biotechnology Inc.3

8/97

4/20

0.15S

$4

2.9

­

$0.6

$0.47

Lexicon Genetics Inc. (LEXG)4

2/9

4/7

10S

$22

47.5

J.P. Morgan & Co. (co-lead) Credit Suisse First Boston (co-lead) CIBC World Markets Punk Ziegel & Co.

$220.0

$203.6

November AG (Neuer Markt: NBX)5

N/A

4/10

2S

EUR17 ($16.24)

N/A

Bayerische Hypo- and Vereins bank AG Bayerische Landesbank Girozentrale

EUR39.7 (US$37.3)

N/A

Packard Bioscience Co. (PBSC)6

3/8

4/19

12S

$9

60.3

Merrill Lynch & Co. Chase H&Q Robert W. Baird & Co. Bank of America Securities Thomas Weisel Partners LLC

$108.0

$98.0

Praecis Pharmaceuticals Inc. (PRCS)7

2/8

4/26

9.2S

$10

40.0

Salomon Smith Barney CIBC World Markets Credit Suisse First Boston

$92.0

$84.3

Sangamo BioSciences Inc. (SGMO)8

2/11

4/6

3.5S

$15

20.8

Lehman Brothers Chase H&Q ING Barings LLC William Blair & Co.

$52.5

$48.8

Tanox Inc. (TNOX)9

2/2

4/6

7.5S

$28.50

41.5

CIBC World Markets FleetBoston Robertson Stephens Warburg Dillon Read LLC Adams, Harkness & Hill Inc KBC Securities

$213.8

$197.6

TOTAL: $999.9M

Number of IPOs year-to date: 20

Number of IPOs in April: 9

Average value of April IPOs: $111.1M

Total raised in IPOs year-to-date: $2166.2M

Average value: $108.3M

Notes:

1 Actelion's offering was conducted in Switzerland. The underwriters have an overallotment option for an additional 100,000 shares.

2 The figures for Exelixis take into account the underwriters' exercise of the overallotment option for 1.365M shares.

3 Ixion registered 8/29/97 to conduct a direct offering over the Internet; the registration statement became effective 12/28/99 and the company said it sold out the financing 4/20/00. Ixion's shares do not trade on an exchange.

4 The underwriters of Lexicon's offering have an overallotment option for an additional 1.5M shares.

5 The underwriters of November's offering have an overallotment option for an additional 400,000 shares.

6 The underwriters of Packard Bioscience's offering have an overallotment option for an additional 360,000 shares.

7 The figures for Praecis take into account the underwriters' exercise of the overallotment option for 1.2M shares.

8 The underwriters of Sangamo's offering have an overallotment option for an additional 525,000 shares.

9 The underwriters of Tanox's offerirng have an overallotment option for an additional 1.125M shares.

FOLLOW-ON OFFERINGS

Avigen Inc. (AVGN)1

2/18

4/13

1S

$26

16.0

Salomon Smith Barney CIBC World Markets ING Barings LLC

$26.0

$23.8

Aviron (AVIR)2

3/8

4/4

2S

$22.50

20.2

Morgan Stanley Dean Witter Bear, Stearns & Co. U.S. Bancorp Piper Jaffray

$45.0

$41.8

Cambridge Antibody Technology plc (LSE:CAT)3

3/7

4/3

4.86

#18.50 U$29.11

33.7

Deutsche Bank AG Cazenove & Co.

#90.0 US$141.6

N/A

Corixa Corp. (CRXA)4

3/7

4/7

1.9S

$32

20.8

Warburg Dillon Read LLC Lehman Brothers Prudential Vector Healthcare, Pacific

$60.8

$56.6

Cubist Pharmaceuticals Inc. (CBST)5

3/10

4/6

2.875S

$33

23.5

FleetBoston Robertson Stephens, Pacific Growth Equities Inc. Chase H&Q ING Barings LLC Lazard Freres & Co. LLC

$94.9

$89.2

Ribozyme Pharmaceuticals Inc. (RZYM)6

3/2

4/6

3.15S

$18

15.2

ING Barings LLC Chase H&Q

$56.7

$52.7

Texas Biotechnology Corp. (AMEX:TXB)7

3/8

4/6

5S

$12.50

34.4

PaineWebber Inc. Prudential Vector Healthcare First Union Securities Inc. Sanders Morris Harris

$62.5

$58.3

TOTAL: $487.5M

Number of follow-on offerings in April: 7

Average value of April follow-ons: $69.6M

Number of follow-on offerings year-to-date: 31

Total raised in follow-ons year-to-date: $7313.0M

Average value of follow-ons year-to-date: $235.9M

Notes:

1 The underwriters of Avigen's offering have an overallotment option for an additional 150,000 shares.

2 The underwriters of Aviron's offering have an overallotment option for an additional 300,000 shares.

3 Cambridge Antibody's offering was conducted in the UK. The underwriters have an overallotment option for an additional 300,000 shares.

4 The offering sold a total of 2M shares for $64M, including 100,000 shares sold by selling stockholders through the exercise of the underwriters' overallotment option. Shares sold by existing stockholders were excluded from the figures above.

5 The figures above for Cubist take into account the exercise of the underwriters' overallotment option for 375,000 shares.

6 Ribozyme offered the 3.15M shares above. The underwriters also exercised an option to acquire additional 472,500 shares of common stock from certain selling stockholders to cover overallotments. Shares sold by existing stockholders were excluded from the figures above.

7 The underwriters of Texas Biotechnology's offering have an overallotment option for an additional 750,000 shares.

II. FILED AND PENDING

Company (Symbol)*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)**

Lead, Other Underwriters

Value ($M)

INITIAL OFFERINGS

Arena Pharmaceuticals Inc. (ARNA)1

4/28

N/A

N/A

N/A

ING Barings LLC Prudential Vector Healthcare SG Cowen Securities

$100.0

Argonaut Technologies Inc. (AGNT)2

4/27

N/A

N/A

N/A

Warburg Dillon Read LLC ING Barings LLC SG Cowen Securities

$86.25

AtheroGenics Inc. (AGIX)3

2/25

N/A

N/A

N/A

SG Cowen Securities Chase H&Q Adams, Harkness & Hill A.G. Edwards & Sons Inc.

$100.0

Cellomics Inc. (CLMX)4

3/3

6S

$16-18

13.6

Prudential Vector Healthcare ING Barings LLC Dain Rauscher Wessels

$102.0

Cepheid (CPHD)5

4/7

N/A

N/A

N/A

Warburg Dillon Read LLC Prudential Vector Healthcare Group Invemed Associates LLC

$92.0

Charles River Laboratories Corp. (NYSE: CRL)6

4/25

N/A

N/A

N/A

Donaldson, Lufkin & Jenrette (co-lead) Lehman Brothers (co-lead) ING Barings LLC SG Cowen Securities U.S. Bancorp Piper Jaffray Inc. DLJdirect Inc.

$230.0

Ciphergen Biosystems Inc. (CIPH)7

3/20

N/A

N/A

N/A

SG Cowen Securities ING Barings LLC Warburg Dillon Read LLC

$86.3

Decode Genetics Inc. (Iceland; DCGN)8

3/8

N/A

N/A

N/A

Morgan Stanley Dean Witter Lehman Brothers

$200.0

Deltagen Inc. (DGEN)9

4/13

N/A

N/A

N/A

Salomon Smith Barney Robertson Stephens U.S. Bancorp Piper Jaffray

$100.0

Dendreon Corp. (DNDN)10

3/8

N/A

N/A

N/A

Prudential Vector Healthcare SG Cowen Securities Pacific Growth Equities Inc.

$100.0

Durect Corp. (DRRX)11

4/20

N/A

N/A

N/A

Morgan Stanley Dean Witter Chase H&Q CIBC World Markets Corp.

$115.0

Esperion Therapeutics (ESPR)12

2/24

N/A

N/A

N/A

FleetBoston Robertson Stephens (co-lead) Chase H&Q (co-lead) U.S. Bancorp Piper Jaffray

$138.0

Genaissance Pharmaceuticals Inc. (GNSC)13

4/20

N/A

N/A

N/A

Deutsche Banc Alex. Brown Inc. Bear Stearns & Co. Inc. Salomon Smith Barney Inc. Warburg Dillon Read LLC

$115.0

Genometrix Inc. (GNMX)14

3/15

N/A

N/A

N/A

Lehman Brothers (co-lead) Chase H&Q (co-lead) Dain Rauscher Wessels Thomas Weisel Partners LLC Fidelity Capital Markets

$120.0

Genomic Solutions Inc.

3/27

5S

$17-19

15.3

Warburg Dillon Read LLC Punk, Ziegel & Co. LP Dain Rauscher Wessels

$90.0

Genomica Corp. (GNOM)16

3/15

6S

$15-17

15.7

CIBC World Markets Dain Rauscher Wessels Prudential Vector Healthcare

$96.0

Girindus AG (Germany; Neuer Markt:GIR)17

N/A

2.6

E18-20 (US$17.10-18)

N/A

Sal. Oppenhim Jr. & Cie KGaA HSBC Trinkhaus & Burkhard KGaA Stadtsparkasse Kvln

E49.4 (US$46.9)

Illumina Inc. (ILMN)18

4/3

N/A

N/A

N/A

Goldman Sachs & Co. Chase H&Q SG Cowen Securities

$100.0

Inspire Pharmaceuticals Inc. (ISPH)19

2/25

5.5S

$13-15

10.8

Bear, Stearns & Co. Inc. Deutsche Banc Alex. Brown U.S. Bancorp Piper Jaffray

$77.0

Introgen Therapeutics Inc. (INGN)20

2/17

N/A

N/A

10.3

SG Cowen Securities Prudential Securities Inc.

$92.0

Ista Pharmaceuticals Inc. (ISTA)21

4/5

N/A

N/A

N/A

CIBC World Markets Corp. ING Barings LLC Prudential Vector Healthcare

$86.25

Kosan Biosciences Inc. (KOSN)22

3/31

N/A

N/A

N/A

Warburg Dillon Read LLC CIBC World Markets Prudential Vector Healthcare

$80.0

Large Scale Biology Corp. (LSBC)23

4/6

N/A

N/A

N/A

J.P. Morgan & Co. Chase H&Q William Blair LLC & Co.

$100.0

NetGenics Inc. (NTGC)24

3/13

5.5S

$12

18.0

Chase H&Q Warburg Dillon Read LLC

$66.0

Orchid BioSciences Inc. (ORCH)25

2/18

8S

$11-13

26

Credit Suisse First Boston FleetBoston Robertson Stephens Salomon Smith Barney

$96.0

Pain Therapeutics Inc. (PTIE)26

3/4

N/A

N/A

N/A

FleetBoston Robertson Stephens CIBC World Markets Lazard Freres & Co. LLC

$75.0

Paradigm Genetics Inc. (PDGM)27

2/18

5S

$14-16

18.9

Chase H&Q J.P. Morgan & Co. Pacific Growth Equities Inc. Stephens Inc.

$75.0

Pharsight Corp. (PHST)28

4/17

N/A

N/A

N/A

Donaldson, Lufkin & Jenrette Chase H&Q Wit Soundview DLJ Direct Inc.

$75.0

Regeneration Technologies Inc. (RTIX)29

4/27

N/A

N/A

N/A

Banc of America Securities LLC Lehman Brothers Inc. Warburg Dillon Read LLC Stephens Inc.

$86.25

Rosetta Inpharmatics Inc. (RSTA)30

3/17

N/A

N/A

N/A

Warburg Dillon Read LLC Lehman Brothers Prudential Vector Healthcare

$115.0

Signal Pharmaceuticals Inc. (SGNL)31

2/18

5S

$13-15

14.2

FleetBoston Robertson Stephens Chase H&Q CIBC World Markets

$70.0

Telik Inc. (TELK)32

4/3

N/A

N/A

N/A

Warburg Dillon Read LLC Chase H&Q Legg Mason Wood Walker Inc.

$75.0

Transgenomic Inc. (TBIO)33

3/10

4S

$12-14

16.0

Chase H&Q Bear, Stearns & Co. Dain Rauscher Wessels

$52.0

Variagenics Inc. (VGNX)34

3/29

N/A

N/A

N/A

Credit Suisse First Boston Chase H&Q SG Cowen Securities

$100.0

Versicor Inc. (VERS)35

3/22

N/A

N/A

N/A

Warburg Dillon Read LLC Lehman Brothers Pacific Growth Equities Inc.

$86.3

ViroLogic Inc. (VLGC)36

2/22

5S

$14-16

14.7

CIBC World Markets ING Barings LLC Prudential Vector Healthcare

$75.0

FOLLOW-ON OFFERINGS

Lorus Therapeutics Inc. (Canada; OTC BB: LORFF)37

4/12

13.3S

C$3 (US$2.03)

HSBC Securities Inc. Yorkton Securities Inc. TD Securities Inc. Dominick & Dominick Securities

C$45.9 (US$31)

Theratechnologies (Canada; TSE:TH)38

4/25

2.1S - 2.6S

C$9.50 (US$6.43)

22.1

Yorkton Securities Inc. BMO Nesbitt Burns Inc. National Bank Financial Inc. Desjardins Securities Inc.

C$20-25 (US$13.5-16.9)

MGI Pharma Inc. (MOGN)39

3/24

2.5

$32.13

15.4

U.S. Bancorp Piper Jaffray Bank of America Securities LLC CIBC World Markets

$80.3

III. WITHDRAWN OR POSTPONED

INITIAL OFFERINGS

Adolor Corp. (ADLR)40

2/8

6S

$12-14

16.8

Warburg Dillon Read LLC FleetBoston Robertson Stephens Pacific Growth Equities Inc.

$78.0

DrugAbuse Sciences Inc. (DASI)41

2/3

4S

$14

12.5

Warburg Dillon Read LLC FleetBoston Robertson Stephens

$56.0

Rigel Pharmaceuticals Inc. (RIGL)42

2/4

9S

$10-12

28.6

Warburg Dillon Read LLC FleetBoston Robertson Stephens Prudential Vector Healthcare

$99.0

FOLLOW-ON OFFERINGS

Cell Therapeutics Inc. (CTIC)43

3/24

3S

$21

21.3

CIBC World Markets U.S. Bancorp Piper Jaffray

$63.0

Cytogen Inc. (CYTO)44

3/28

6S

$9.109

72.7

Warburg Dillon Read LLC CIBC World Markets

$54.7

EntreMed Inc. (ENMD)45

3/31

2S

$59.875

15.0

Bank of America Securities LLC (co-lead) Warburg Dillon Read LLC (co-lead) Gerard Klauer Mattison & Co.

$119.8

Genome Therapeutics Corp. (GENE)46

3/16

3S

$24.6875

20.6

CIBC World Markets Warburg Dillon Read LLC Dain Rauscher Wessels Tucker Anthony Cleary Bull

$74.1

Genzyme Molecular Oncology (GZMO)47

3/9

3S

$24.25

14.9

SG Cowen Securities PaineWebber Inc. Chase H&Q

$72.8

Geron Corp. (GERN)48

3/13

3S

$44.13

21.2

J.P. Morgan FleetBoston Robertson Stephens Salomon Smith Barney

$132.4

LJL Biosystems Inc. (LJLB)49

3/14

2.5

$19.13

14.8

FleetBoston Robertson Stephens Chase H&Q Pacific Growth Equities

$47.8

Myriad Genetics Inc. (MYGN)50

3/3

2S

$164

10.3

Morgan Stanley Dean Witter Dain Rauscher Wessels CIBC World Markets Tucker Anthony Clear Gull

$328.0

Onyx Pharmaceuticals Inc. (ONXX)51

3/27

2.5

$18.375

14.0

U.S. Bancorp Piper Jaffray Chase H&Q CIBC World Markets

$45.9

Transgene SA (France; TRGNY)52

3/7

1.2S

$54

17.2

Lehman Brothers

$64.8

Notes:

* Stock symbols for companies seeking to complete IPOs are proposed.

** Shares outstanding exclude new shares to be issued in the offering.

1 Arena's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $100M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

2 Argonaut's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $86.25M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

3 AtheroGenics' prospectus was amended 3/6/00. The filing leaves blank the number of shares, price per share and shares outstanding. The estimated value of the IPO, $100M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

4 Cellomics' prospectus was amended 4/14/00. The estimated value of the IPO, $102M, is based on the sale of 6M shares at $17, the midpoint of the expected price range. The underwriters have an overallotment option for 900,000 shares.

5 Cepheid's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $92M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

6 Charles River's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $230M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

7 Ciphergen's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $86.3M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

8 Decode's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $200M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

9 Deltagen's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $100M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

10 Dendreon's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $100M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees. Kirin Brewery Co. Ltd. (Japan) will purchase $5M (net) worth of Dendreon's common stock in a private placement concurrent with the IPO.

11 Durect's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $115M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

12 Esperion's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $138M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

13 Genaissance's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $115M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

14 Genometrix's prospectus was amended 4/19/00. The filing leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $120M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

15 Genomic Solutions' prospectus was amended 3/20/00, 3/27/00, 3/28/00, 4/5/00, 4/14/00, 4/19/00 and 4/27/00. The estimated value of the IPO, $90M, is based on the sale of 5M shares at $18, the midpoint of the expected price range. The underwriters have an overallotment option for 750,000 shares.

16 Genomica's prospectus was amended 3/16/00, 4/19/00 and 4/20/00. The estimated value of the IPO, $96M, is based on the sale of 6M shares at an assumed price of $16 per share. The underwriters have an overallotment option for an additional 900,000 shares.

17 Girindus' offering will be conducted in Germany. The underwriters have an overallotment option for 345,000 shares.

18 Illumina's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $100M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

19 Inspire's prospectus was amended 2/25/00. The estimated value of the IPO, $77M, is based on the sale of 5.5M shares at $14 per share, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 825,000 shares.

20 Introgen's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $92M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

21 Ista's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $86.25M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

22 Kosan's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $80M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

23 Large Scale's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $100M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

24 The estimated value of NetGenics' IPO, $66M, is based on the sale of 5.5M shares at an assumed price of $12 per share. The underwriters have an overallotment option for an additional 825,000 shares.

25 Orchid's prospectus was amended 4/7/00 and 4/10/00. The estimated value of the IPO, $96M is based on the sale of 8M shares at $12 per share. The underwriters have an overallotment option for 1.2M shares.

26 Pain Therapeutics' prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $75M, , is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

27 The estimated value of Paradigm's offering, $75M, is based on the sale of 5M shares at $15, the midpoint of the expected price range.

28 Pharsight's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $75M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

29 Regeneration's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $86.25M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

30 Rosetta's prospectus was amended 4/15/00. The filing leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $115M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

31 Signal's prospectus was amended 3/22/00. The estimated value of the IPO, $70M, is based on the sale of 5M shares at $14 per share, the midpoint of the expected price range. DuPont Pharmaceuticals Co. (NYSE:DD) will buy $2M worth of shares in a private placement concurrent with the IPO. The underwriters have an overallotment option for 750,000 shares.

32 Telik's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $75M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

33 The estimated value of Transgenomic's IPO, $52M, is based on the sale of 4M shares at an assumed price of $13 per share. The underwriters have an overallotment option for an additional 600,000 shares.

34 Variagenics' prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $100M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

35 Versicor's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $86.3M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

36 ViroLogic's prospectus was amended 4/7/00. The estimated value of the IPO, $75M, is based on the sale of 5M shares at $15 per share, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 750,000 shares.

37 Lorus' prospectus was filed in Canada. The underwriters have an overallotment option for an additional 2M shares.

38 Theratechnologies said it planned to raise C$20M to C$25M (US$13.5M to $16.9M) in a public offering conducted in conjunction with a private financing for its Ecopia Biosciences spin-off. Based on the 4/24/00 closing price of C$9.50 (US$6.43), the offering would comprise 2.1M to 2.6M shares.

39 The estimated value of MGI's offering, $109.2M, is based on the sale of 2.5M shares at an assumed price of $43.69 per share. The underwriters have an overallotment option for an additional 375,000 shares.

40 Adolor said on 4/13/00 it was postponing its IPO due to market conditions.

41 DrugAbuse said on 4/13/00 it was postponing its IPO due to market conditions.

42 Rigel said on 4/13/00 it was withdrawing its IPO due to market conditions.

43 Cell Therapeutics said on 4/17/00 it was withdrawing its offering due to market conditions.

44 Cytogen said on 4/17/00 that it would covert its filing to a shelf registration due to market conditions.

45 EntreMed said on 4/13/00 it would cancel the offering due to market conditions.

46 Genome Therapeutics said on 4/13/00 it would convert its filing to a shelf registration due to market conditions.

47 Genzyme Molecular said on 4/18/00 it would not proceed with the offering due to market conditions.

48 Geron said on 4/19/00 it would not proceed with the offering due to market conditions

49 LJL said on 4/10/00 it would not proceed with the offering due to market conditions.

50 Myriad withdrew its registration statement 4/12//00 due to market conditions.

51 Onyx said on 4/19/00 it would not proceed with the offering due to market conditions.

52 Transgene said on 4/14/00 it would not proceed with the offering due to market conditions.

No Comments